Patents by Inventor Marco Alexander Poleganov

Marco Alexander Poleganov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230272406
    Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3?-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.
    Type: Application
    Filed: September 28, 2022
    Publication date: August 31, 2023
    Inventors: Alexandra Orlandini Von Niessen, Stephanie Fesser, Britta Vallazza, Tim Beissert, Andreas Kuhn, Ugur Sahin, Marco Alexander Poleganov
  • Patent number: 11492628
    Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3?-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: November 8, 2022
    Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
    Inventors: Alexandra Orlandini Von Niessen, Stephanie Fesser, Britta Vallazza, Tim Beissert, Andreas Kuhn, Ugur Sahin, Marco Alexander Poleganov
  • Publication number: 20200362313
    Abstract: The present invention describes a virus-derived factor which when provided to cells, e.g., by transfecting the cells with RNA encoding the virus-derived factor, enhances expression of RNA encoding a peptide or protein in the cells. In particular, the virus-derived factor enhances survival of cells, in particular when transfected repetitively with RNA, and reduces an IFN response of cells to transfected RNA. Accordingly, the present invention provides methods and means for enhancing expression of RNA in cells. The cells are preferably transfected with the RNA.
    Type: Application
    Filed: September 11, 2018
    Publication date: November 19, 2020
    Inventors: Marco Alexander Poleganov, Mario Perkovic, Ugur Sahin, Tim Beissert, Andreas Kuhn
  • Publication number: 20200277627
    Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin and comprises an open reading frame encoding a reprogramming factor. Such RNA replicons are useful for expressing a reprogramming factor in a cell, in particular a somatic cell. Cells engineered to express such reprogramming factors are useful in cell transplantation therapies.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Inventors: Marco Alexander POLEGANOV, Mario PERKOVIC, Ugur SAHIN, Tim BEISSERT
  • Publication number: 20190071682
    Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3?-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.
    Type: Application
    Filed: October 5, 2016
    Publication date: March 7, 2019
    Inventors: Alexandra Orlandini Von Niessen, Stephanie Fesser, Britta Vallazza, Tim Beissert, Andreas Kuhn, Ugur Sahin, Marco Alexander Poleganov